Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H42BN3O6 |
| Molecular Weight | 491.428 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1)B(O)O
InChI
InChIKey=MWKOOGAFELWOCD-FKBYEOEOSA-N
InChI=1S/C25H42BN3O6/c1-16(2)12-20(24(31)29-22(26(33)34)14-18(5)6)27-23(30)21(13-17(3)4)28-25(32)35-15-19-10-8-7-9-11-19/h7-11,16-18,20-22,33-34H,12-15H2,1-6H3,(H,27,30)(H,28,32)(H,29,31)/t20-,21-,22-/m0/s1
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. | 1998 Feb 17 |
|
| Role of the proteasome in the regulation of fetal fibronectin secretion in human placenta. | 2001 Sep |
|
| Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. | 2002 Aug 28 |
|
| Proteasome inhibitors induce peroxisome proliferator-activated receptor transactivation through RXR accumulation and a protein kinase C-dependent pathway. | 2005 Mar 10 |
|
| Identification of the proteasome inhibitor MG262 as a potent ATP-dependent inhibitor of the Salmonella enterica serovar Typhimurium Lon protease. | 2006 Jul 11 |
|
| Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors. | 2006 May 18 |
|
| Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines. | 2007 Apr |
|
| Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. | 2008 Jun |
|
| Lon peptidase 1 (LONP1)-dependent breakdown of mitochondrial 5-aminolevulinic acid synthase protein by heme in human liver cells. | 2011 Jul 29 |
|
| Scutellarin inhibits high glucose-induced and hypoxia-mimetic agent-induced angiogenic effects in human retinal endothelial cells through reactive oxygen species/hypoxia-inducible factor-1α/vascular endothelial growth factor pathway. | 2014 Sep |
Patents
Sample Use Guides
MG-262 is capable of reducing the viability of human nasal mucosa and polyp fibroblasts (IC50 values: 48 h, 11 nM; 72 h, 4 nM), and inducing cell death via loss of mitochondrial membrane potential, caspase-3 and poly(ADP-ribose) polymerase activation (treatment with 50 nM MG262 for 24 h did not result in the expression of cleaved caspase-3, or its substrate PARP, in any fibroblast line tested).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID80170795
Created by
admin on Fri Dec 15 21:50:26 GMT 2023 , Edited by admin on Fri Dec 15 21:50:26 GMT 2023
|
PRIMARY | |||
|
179324-22-2
Created by
admin on Fri Dec 15 21:50:26 GMT 2023 , Edited by admin on Fri Dec 15 21:50:26 GMT 2023
|
PRIMARY | |||
|
490002
Created by
admin on Fri Dec 15 21:50:26 GMT 2023 , Edited by admin on Fri Dec 15 21:50:26 GMT 2023
|
PRIMARY | |||
|
549V4DP94W
Created by
admin on Fri Dec 15 21:50:26 GMT 2023 , Edited by admin on Fri Dec 15 21:50:26 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
